About us

The SWL Integrated Medicines Optimisation Committee (IMOC) is a strategic partnership committee. It is responsible for oversight, implementation and performance management of medicines related decisions within prescribing allocations, operating under the overarching governance of SWL Integrated Care Board (ICB).

Refer to the SWL IMOC terms of reference for further information. Please note the sub-committees in appendix 3 have not been operationalised. The following sub-groups remain accountable to IMOC:

  • Joint Formulary Committee (JFC)
  • High Cost Drugs and Pathways Group (HCD&P)
  • Medicines Optimisation Safety Learning Network (MOSILN)
  • Metal Health Integrates Prescribing Forum (MHIPF)

Remit

  • Provides collective clinical leadership for medicines optimisation (MO) in SWL, promoting integrated health partnerships, co-design and developing neighbourhood teams, ensuring patients have consistent access to medicines with safe, clinically and cost-effective outcomes within existing resources.
  • Provides clinical leadership for global public health priorities including antimicrobial resistance and opioid stewardship
  • Provides advice to ICB strategic commissioners and contractors, using population health management and epidemiology, and utilising prescribing data to promote access to high quality care, improved outcomes and reduced inequalities.
  • Provides governance and oversees the delivery of the SWL Medicines and Medicines Value Strategy, a transformation plan that prioritises allocations of resources, enhances value, promotes safer medicine use, and drives innovative care models
  • Provides governance over:
    • Policies and medicine-related clinical pathway re-design and transformation.
    • Financial and clinical risk relating to medicines
  • Provides assurance on access to medicines, addressing inequalities and unwarranted variation.
  • Promotes the use of digital and data solutions to improve systems and communication relating to medicines.
  • Responds to and oversees impact assessments for disrupter technologies, including pharmacogenomics, the implementation of regional and national advice and National Institute for Health and Care Excellence (NICE) appraisal recommendations to encourage rapid and consistent uptake.
  • Provides a forum for collaborative partnership working with NHS-E to support readiness and implementation of NHS-E delegated functions.

Guideline Policy Development

Refer to: